19P - OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer

Date 08 May 2014
Event IMPAKT 2014
Session Welcome reception and Poster Walk
Topics Breast Cancer
Translational Research
Presenter Thomas Karn
Citation Annals of Oncology (2014) 25 (suppl_1): i5-i7. 10.1093/annonc/mdu065
Authors T. Karn1, N. Sänger1, E. Ruckhäberle2, G. Bianchini3, V. Müller4, A. Rody5, E.F. Solomayer6, T. Fehm2, U. Holtrich1, S. Becker1
  • 1Dept. Of Gynecology And Obstetrics / Breast Unit, Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), 60590 - Frankfurt am Main/DE
  • 2Department Of Obstetrics And Gynecology, Heinrich-Heine-University Duesseldorf, Düsseldorf/DE
  • 3Department Of Medical Oncology, Ospedale San Raffaele, Milan/IT
  • 4Department Of Obstetrics And Gynecology, University Hospital Hamburg-Eppendorf, Hamburg/DE
  • 5Dept. Of Gynecology And Obstetrics / Breast Unit, University SH.-Lübeck, Lübeck/DE
  • 6Department Of Obstetrics And Gynecology, University Medical School of Saarland, Homburg/DE


The RANK/RANKL/OPG pathway is well known for bone destruction in skeletal metastases but has also been implicated in osteoclast-independent roles in tumorigenesis and de novo metastasis. Experimental data suggest contribution of progesterone to tumorigenesis may be mediated by RANKL. Importantly, modulation of this pathway became possible through the availability of denosumab, an artificial counterpart of OPG, but significant gaps remain in the translation of preclinical findings on the pathway. We analyzed gene expression of RANK, RANKL and OPG from 40 Affymetrix datasets encompassing 4467 primary breast cancers and focused on ER positive disease.

We did not observe a significant prognostic value of RANK and RANKL mRNA expression. In contrast, OPG was associated with a better prognosis among 1941 ER positive cancers (HR 0.64, 95 CI 0.530.77; P